moneyheap
PGNY · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Progyny, Inc. Common Stock (PGNY) stock moving?
Progyny beat Q3 2026 expectations on November 4, with adjusted EPS of $0.52 against a $0.31 estimate and sales slightly ahead of consensus. Management raised FY2026 adjusted EPS guidance to $2.09-$2.13 and lifted the low end of sales guidance to $1.365B. Q4 adjusted EPS guidance of $0.53-$0.58 is well above the $0.34 estimate, while the Q4 sales range brackets consensus, so the upside is concentrated in profitability rather than top-line growth. Analysts responded quickly: Leerink, Wells Fargo, Citizens and Cantor raised targets to $35-38 with Outperform or Overweight-type ratings, while JP Morgan stayed Neutral and lifted its target from $30 to $35. The stock jumped from $30.10 to $34.37 on November 5 on about 2.79M shares, roughly three times its recent daily volume, and has kept climbing since, closing at $36.43 on November 10, the highest close in the 30-day window and about 29% above the October 26 low of $28.13. The share price now sits above JPM's $35 target and close to the $38 targets, so much of the near-term upside from the earnings re-rating appears priced in. A CEO sale of about 173,000 shares worth $6.18M on November 5 is a negative datapoint, although it may be a planned transaction. Overall the fundamental news flow is positive, but the rally has run ahead of most published targets.
News behind the analysis
- Progyny, Inc. Reports Financial Results for the Third Quarter of 2026Progyny reported Q3 2026 results and provided updated fourth-quarter 2026 guidance. The company filed the release with the SEC in an 8-K on November 4.
- Progyny Q3 Adj. EPS $0.52 Beats $0.31 Estimate, Sales $341.254M Beat $340.924M EstimateThird-quarter adjusted EPS of $0.52 beat the $0.31 estimate, and sales of $341.3M edged past the $340.9M estimate.
- Progyny Raises FY2026 Adj EPS Guidance from $2.04-$2.10 to $2.09-$2.13 vs $1.28 Est; Raises FY2026 Sales Guidance from $1.360B-$1.385B to $1.365B-$1.385B vs $1.373B EstFull-year 2026 adjusted EPS guidance was raised to $2.09-$2.13, and the low end of sales guidance was lifted to $1.365B.
- Progyny Sees Q4 Adj EPS $0.53-$0.58 vs $0.34 Est; Sees Sales $344.700M-$364.700M vs $353.596M EstFourth-quarter adjusted EPS guidance of $0.53-$0.58 sits well above the $0.34 estimate, while the sales range brackets the $353.6M estimate.
- Leerink Partners Maintains Outperform on Progyny, Raises Price Target to $38Leerink Partners kept its Outperform rating and raised its price target to $38.
- Wells Fargo Maintains Overweight on Progyny, Raises Price Target to $38Wells Fargo reaffirmed its Overweight rating and raised its price target from $37 to $38.
- Progyny CEO Peter Anevski Sells Shares Worth Over $6 MillionCEO and Director Peter Anevski sold 173,247 shares on November 5 for about $6.18 million. The sale is a notable insider transaction, though it may be routine.
- JP Morgan Maintains Neutral on Progyny, Raises Price Target to $35JP Morgan kept its Neutral rating and raised its price target from $30 to $35, close to the current share price.
About Progyny, Inc. Common Stock
Progyny is a New York-based benefits manager that sells fertility, family-building and women's health benefits to self-insured employers. It stands out for its own bundled treatment design ("Smart Cycles"), a hand-picked network of fertility clinics, in-house care advocates who support patients, and very high client retention.
How it makes money
Most revenue comes from employer clients paying for fertility treatments and care management for their employees. A large share, roughly 40% in past years, comes from Progyny Rx, an add-on pharmacy benefit that handles fertility drugs through specialty pharmacies. The company also has newer services covering pregnancy and postpartum, menopause, and parenting support. It has more than 600 clients and about 7 million covered lives, and full-year 2026 revenue was guided at roughly $1.37–1.39 billion.
What usually moves PGNY
- Member use of treatment (how many covered employees start fertility care)
- New clients and covered lives won in the annual selling season
- Retaining or losing large employer clients
- Employer spending on benefits and medical cost inflation
- Competition from rival fertility benefit providers and health plans